Fig. 2

Correlation of CITED1 protein (TMA) and gene expression (TGCA) with prognosis following anti-endocrine treatment. For the TMA analysis, patients were classified into 2 groups either as having low (negative/faint: blue line) or high (moderate/strong: orange line) CITED1 protein expression following IHC; A Relapse-free survival (RFS) following breast cancer diagnosis in the ER+ , TAM-treated cohort. B Breast cancer specific survival (BCSS) following diagnosis in the ER+ , TAM-treated cohort. The number of patients in each group at diagnosis is indicated in brackets. TCGA was used for validation of differential CITED1 gene expression (high expression: orange line, low expression: blue line) and its association with prognosis; C Relapse-free survival in all ER+/LN− TCGA breast tumours following any anti-endocrine (AE) treatment. D Relapse-free survival in the ER+/LN− breast tumours treated with aromatase inhibitors (AI). The number of patients in each group at diagnosis is indicated in brackets